---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-273393"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:39:50.873738+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports positive Phase 2 bezuclastinib data in AdvSM and NonAdvSM at ASH 2024

## Summary
- APEX (AdvSM): 52% ORR per mIWG-MRT-ECNM; 61% in TKI-naïve; 83% at 100 mg BID. Median PFS not reached; 24-mo PFS rate 82%.
- 100% PPR ORR at 100 mg BID; 94% of patients had >=50% tryptase reduction; 93% had >=50% KIT D816V VAF reduction.
- SUMMIT (NonAdvSM): 56% mean TSS improvement; 76% of patients had >50% MS2D2 reduction; 49% mean MC-QoL improvement at 24 wks.
- 95% of patients with baseline tryptase >=20 ng/mL achieved <20 ng/mL by week 24; 84% with baseline >11.4 ng/mL achieved <11.4.
- SUMMIT Part 2 enrollment complete (179 patients); top-line expected July 2025. APEX Part 2 enrollment completion Q1 2025; top-line mid-2025.

## SEC filing metadata
- accession: 0001193125-24-273393
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312524273393/0001193125-24-273393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312524273393/d914555d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-273393
- JSON: https://secwatch.observer/filing/0001193125-24-273393.json
- Plain text: https://secwatch.observer/filing/0001193125-24-273393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.